Services Provider Haixin Zhihui Raises CNY Hundreds of Mns in Series B Funding

Zhejiang Haixin Zhihui (Chinese: 浙江海心智惠) announced the completion of a Series B financing round worth several hundreds of millions of CNY today. Haixin Zhihui is a leading Chinese intelligent service platform in the field of oncology diagnosis and treatment that provides the full course of tumor patient management.

The B1 round of financing was led by Qiming Venture Capital(Chinese:启明创投), with follow-on participation from existing shareholder Hepei Investment (Chinese:禾沛投资).

The B2 round of financing was led by Tailong Capital (Chinese:泰珑投资)., followed by Xiamen Baotuo (Chinese: 厦门宝拓), and Zhenghe Benyuan (Chinese: 正和本源).

The proceeds of this round of funding will be used to further introduce talents into the core team and to continuously improve the construction of the tumor intelligent service business line.

To date, Haixin Zhihui has successfully built a tumor-intelligent whole-course management platform. The main product matrix and services include multi-tumor CDSS, digital therapy, clinical new drug R&D support, and out-of-hospital products and services for patients.

Haixin Zhihui's CSCO AI intelligent decision-making system is the only intelligent auxiliary diagnosis and treatment system branded and endorsed by the Chinese Society of Clinical Oncology (CSCO). It can efficiently empower oncology clinical departments at all levels, improve the overall level of oncology diagnosis and treatment in China, and facilitate the tumor treatment capabilities of a large number of departments to CSCO standards. To date, it has launched breast cancer, lung cancer, esophageal cancer, gastric cancer, and colorectal cancer and is expected to expand the coverage of all cancer types in the next few years.

Haixin Zhihui's main competitors include Dianei Technology (Chinese:点内科技), DHCtech (Chinese: 神州医疗), and PV Medtech (Chinese: 柏视医疗).